| Domain |
Key Finding |
Source |
| The blood level is the mechanism |
Oral vs. injectable semaglutide at identical plasma concentrations produce statistically identical HbA1c reduction, weight loss, cardiovascular biomarker changes, and nausea rates. Route of administration is irrelevant; circulating drug level is everything |
Overgaard et al., Cell Rep Med 2021 |
| What this rules out |
A preferential gut-brain GLP-1R axis, portal vein GLP-1R activation, local GI receptor engagement, and interindividual differences in GLP-1R sensitivity are all ruled out as major determinants of semaglutide's therapeutic effect |
Overgaard et al., 2021 |
| GLP-1's weight mechanism |
Appetite suppression (~35% reduction in ad libitum energy intake), not energy expenditure. Four controlled human trials show no change in resting EE. Gut GLP-1 knockout mice have normal body weight. The mechanism is CNS, not metabolic |
Drucker, Mol Metab 2022; Friedrichsen et al. 2021 |
| The critical brain site |
Hindbrain DVC is obligate — ablation blocks drug effect; hypothalamic ARC/PVN deletion does not. Within DVC: NTS→PVH drives satiety without aversion; AP→lPBN drives aversion. Only 6% of neurons respond to both. Satiety and nausea are separable circuits |
Huang et al., Nature 2024; Burmeister et al., Diabetes 2017 |
| STEP 4 as proof of concept |
Randomized withdrawal trial: both arms continued structured lifestyle. The only variable was the drug. Continued semaglutide → further weight loss. Placebo → rapid regain toward 3–5% net loss (typical lifestyle-only outcome). The pharmacology was doing the entire work |
Rubino et al., JAMA 2021 |
| Why weight returns |
When levels drop, the counter-regulatory system resurfaces: ghrelin rises, satiety hormones (PYY, CCK, amylin) fall and remain suppressed for ≥12 months, metabolic adaptation persists (~300 kcal/day below predicted at 10% below baseline). Tzang meta-analysis: 7.31 kg rebound at >26 weeks; semaglutide rebounds more than liraglutide (8.21 vs. 4.29 kg) |
Sumithran et al. 2011; Tzang et al. 2025; Leibel et al. 1995 |
| Clinical implication |
Semaglutide suppresses the neurohormonal forces that drive excess weight and weight regain. When the drug is stopped, those forces return. The biology of obesity doesn't end with treatment — it pauses. Chronic pharmacotherapy is the logical corollary of a chronic neurobiological disease |
Convergent evidence |
